NCT01189318

Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder

Effects of Seroquel XR (Quetiapine Fumarate Extended-Release) on Sleep Architecture in Patients With Major Depressive Disorder

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ewha Womans University · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

In this study, patients with major depressive disorder (MDD) who have insomnia symptom are treated with Seroquel XR in an open-label manner for a 4-week period with repeated measurements of insomnia symptoms and sleep parameters using polysomnography.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Quetiapine Fumarate Extended Release	Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2010-08-26
• Last updated: 2015-08-07

Locations

1 site across 1 country: South Korea